BIA Networking Lunch - Glasgow

Dr Ian W Campbell

Executive Chair, Innovate UK

Dr Ian Campbell is an experienced executive in life sciences and the diagnostics sector. In October 2016 Ian took up the post of Director for Health and Life Sciences at Innovate UK. Prior to that, he most recently served as Chief Executive of Arquer Diagnostics, a company developing and commercialising immunoassay tests for cancers of the urinogenitary tract. Previously he served as Chief Executive of Imperial College spin-out company Molecular Vision, developing a disposable, quantitative point-of-care diagnostic platform, before being acquired by Abingdon Health in 2012. Ian has also served as Commercial Director with Bespak Europe. Ian has a strong scientific background, gaining his PhD at the University of Glasgow.

Dr Tina Flatau

Chief Business Officer, Sixfold Bioscience

Tina Flatau is an altruistic life sciences professional firmly interested in pursuing new therapy technologies. She has a wide-ranging career with PwC and in biopharma, working across the spectrum from global multinational companies to a series of technology-based start-ups. Inventor of two PCT patents with therapeutic monoclonal antibodies (currently in a PhII clinical trial), she worked at pioneering antisense-RNA developer Prosensa and has been a Board member of patient-led charity Action Duchenne since 2017 and Chair through 2019-2020. A Board member for RNA-delivery start-up Sixfold Bioscience, she focuses on tech company funding and growth, where innovation and financial expertise, and a readily-available source of specialist scientists, are indispensable. She is a regular member of the BIA’s Finance and Tax Advisory Committee to ensure that SME biotech voice is heard. Tina is an NHS Health Research Authority Ethics Committee Lay Member, advocating for closer involvement of patients as partners in R&D.

Dr Deborah O'Neil

Chief Executive Officer, NovaBiotics

A biotechnologist with two decades of experience in the field of anti-infectives research & drug development, Deborah studied immunology at University College London and then worked in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen. It was here where, in order to fully develop the commercial potential of her platform of novel antibacterial and antifungal therapies, she founded NovaBiotics in 2004. Deborah has since grown the business - as its Chief Executive & Scientific Officer - into a leading global biotechnology company with a portfolio of clinical-stage and preclinical anti-infective drug candidates for medically unmet infectious diseases. Deborah is editor of the European Biopharmaceutical Review and International Pharmaceutical Technology, a member of the Scottish Life Science Industry Leadership Group and sits on the Advisory Board of the Scottish Life Sciences Association. Deborah is also a member of the newly formed Life Sciences board of Opportunity North East and an elected Board Member of Aberdeen & Grampian Chamber of Commerce as well as being a proud Trustee of Crohn’s in Childhood Research Association.

Dr Martin Turner

Associate Director, Policy, Public Affairs & Investor Relations

What does your role at BIA involve?
Martin is responsible for all the BIA's policy outputs and public affairs activities and leads on finance and tax policy as well as the BIA’s engagement with the investment community. He authors the BIA’s investment analysis reports and is a regular commentator on the life sciences sector in the national press. He also serves on the Advisory Board of the Cambridge University Science Policy Exchange (CUSPE).

Previous experience & achievements
Martin has over ten years experience in policy and public affairs and has worked at the Royal Society, the Campaign for Science and Engineering, and the Association of Medical Research Charities. Before embarking on a career in policy, he completed a PhD in molecular biology at the University of Sheffield, where he also co-founded and was director of an award-winning science communication charity called Science Brainwaves. He has a BSc in molecular biology from the University of Manchester.